- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00777764
The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 4
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- (Applicable to healthy subjects only) Healthy subjects not taking any regular prescription medication, without history of allergy, and considered healthy by the physician
- (Applicable to asthma patients only) Patients with atopic asthma diagnosed by a physician with asthma and history of positive skin test(s)
- Physical examination findings within normal limits
- Body mass index (BMI) between 18 and 30, inclusive
Exclusion Criteria:
- Pregnancy and lactation
- Current or previous treatment with a biologic agent (e.g., monoclonal antibody)
- Concurrent disease or condition that would interfere, or for which the treatment might interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to individuals in this study
- History or symptoms of significant psychiatric disease, including but not limited to, depression, schizophrenia, etc.
- History of drug abuse
- Participation in an investigational drug or device trial within the last 30 days prior to screening
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Healthy Volunteers
Healthy participants were tested sequentially in a skin prick test procedure with positive control (histamine 6 mg/mL), negative control (saline), and 1:1000, 1:100, 1:10 dilution and full concentrations of both omalizumab and omalizumab excipients.
|
In sterile water for injection (SWFI), full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:1000, 1:100 and 1:10 were followed by 20 minutes of observation. For the skin prick test, participants were tested initially with positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration. For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration. Dilutions of omalizumab and its excipients were in SWFI. |
Experimenteel: Allergic Asthma Participants
Allergic asthma participants were tested sequentially in a skin prick test procedure with positive control (histamine 6 mg/mL), negative control (saline), and a succession of 1:1000, 1:100, 1:10 dilutions and full concentration of both omalizumab and omalizumab excipients.
|
In a saline solution, full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:100,000 and 1:10,000 were followed by 20 minutes of observation. For the skin prick test, participants were tested initially by positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration. For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration. Dilutions of omalizumab and its excipients were made in saline. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Number of Participants by of Adverse Events Following a Skin Test Procedure
Tijdsspanne: Up to 7 days following skin testing
|
Skin test procedures were skin prick test or intradermal test. The test started with the lowest concentration. If a positive skin reaction was observed, escalation to the next dilution was stopped. Subjects were observed for 20 minutes following each test; subjects were observed for 1 hour after the last intradermal test. Those with a positive response were observed for an additional 6 hours. Severity refers to the intensity of an AE (mild, moderate or severe). Mild is itching or hives, for example. A severe event requires emergency medical treatment and can result in death. |
Up to 7 days following skin testing
|
Number of Participants Who Experienced a Positive Skin Reaction (Skin Prick Test)
Tijdsspanne: on the day of skin test
|
For skin prick, positive control (histamine 6 mg/mL) and negative control (saline) were used.
Positive skin reaction was defined as a ≥ 3-mm wheal and/or > 10-mm erythema from negative control.
The skin prick test started with the lowest concentration.
If a positive skin reaction was observed, escalation to the next dilution was stopped.
|
on the day of skin test
|
Number of Participants Who Experienced a Positive Skin Reaction (Intradermal Test in Healthy Volunteers)
Tijdsspanne: on the day of skin test
|
For intradermal testing, positive control (histamine 0.1 mg/mL) and negative control (saline) were used.
Positive skin reaction was defined as a ≥ 3-mm wheal and/or > 10-mm erythema from negative control.
The intradermal test started with the lowest concentration.
If a positive skin reaction was observed, escalation to the next dilution was stopped.
|
on the day of skin test
|
Number of Participants Who Experienced a Positive Skin Reaction (Intradermal Test in Patients With Allergic Asthma)
Tijdsspanne: on the day of skin test
|
For intradermal testing, positive control (histamine 0.1 mg/mL) and negative control (saline) were used.
Positive skin reaction was defined as a ≥ 3-mm wheal and/or > 10-mm erythema from negative control.
The intradermal test started with the lowest concentration.
If a positive skin reaction was observed, escalation to the next dilution was stopped.
|
on the day of skin test
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Dennis Wong, M.D., Genentech, Inc.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- Q4465g
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Gezond
-
University of LeicesterNational Institute for Health Research, United KingdomVoltooidPatiënten met hartfalen en behouden ejectiefractie - HFpEF | Patiënten met hartfalen met verminderde ejectiefractie - HFrEF | Healthy Controls Group - Leeftijd en geslacht afgestemd
-
University Hospital, GrenobleUniversity Hospital, Clermont-Ferrand; Grenoble Institut des NeurosciencesBeëindigdZiekte van Parkinson | Healthy Controls Group - Leeftijd en geslacht afgestemdFrankrijk
Klinische onderzoeken op Cohort I
-
Weill Medical College of Cornell UniversityBeëindigd
-
Memorial Sloan Kettering Cancer CenterWervingKleincellig longcarcinoom | Kleincellige longkankerVerenigde Staten
-
M.D. Anderson Cancer CenterActief, niet wervendLymfoedeemVerenigde Staten
-
American Regent, Inc.Voltooid
-
Jeil Pharmaceutical Co., Ltd.VoltooidMiddelen tegen zwerenKorea, republiek van
-
Y Biologics Inc.Novotech (Australia) Pty LimitedActief, niet wervendGeavanceerde solide tumorenKorea, republiek van, Thailand, Australië
-
Institut du Cancer de Montpellier - Val d'AurelleNog niet aan het werven
-
Kangabio AUSTRALIA LTD PTYNog niet aan het wervenGevorderde of gemetastaseerde solide tumorenAustralië
-
MedImmune LLCVoltooidGezondVerenigde Staten, Australië, Spanje, Duitsland, Canada, Finland, Zuid-Afrika, Brazilië, Israël